triamcinolone acetonide
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
2198
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
March 12, 2026
Multimodal Management of Keloid and Hypertrophic Scars: A Review of Current Therapeutic Strategies
(AAD 2026)
- " Comprehensive literature synthesis examined treatment modalities including intralesional injectables (triamcinolone acetonide [TAC], 5-flurouracil [5-FU], botulinum toxin-A [BTX-A], verapamil, platelet-rich plasma [PRP]), energy-based devices (laser, radiotherapy), and surgical options with adjuvant therapies... Multimodal, individualized approaches combining injectables, energy-based devices, in addition to surgical excision with adjuvant therapy yield optimal outcomes for keloid and hypertrophic scars, improving characteristics and reducing recurrence with acceptable safety."
Review • Fibrosis
March 03, 2026
A Comparative Study of Intralesional Triamcinolone Acetonide Versus Fractional Carbon-dioxide laser assisted delivery of topical tofacitinib in alopecia areata
(AAD 2026)
- "However the difference between the two groups was not statistically significant (p=0.061) .Trichoscopic activity resolved in all patients by 12 weeks with minimal side effects in both the groups. Our findings suggest that fractional laser-assisted drug delivery of topical tofacitinib may provide a viable alternative to intralesional triamcinolone in patchy AA."
Aesthetic Medicine • Alopecia • Immunology
January 05, 2026
A Comparative Study on the Efficacy and Safety of Fractional CO2 Laser-Assisted Delivery of Methotrexate Versus Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata
(AAD 2026)
- No abstract available
Clinical • Alopecia • Immunology
March 28, 2026
Long-acting triamcinolone acetonide prodrug microcrystals for sustained intra-articular treatment of osteoarthritis.
(PubMed, J Control Release)
- "Histological analyses confirmed significant attenuation of cartilage degeneration and synovitis without systemic toxicity. These findings establish PKTA MCs as a promising minimally invasive, long-acting platform for OA management."
Journal • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology • MMP13
March 28, 2026
Dose Dependent Steroid Injections
(clinicaltrials.gov)
- P4 | N=150 | Not yet recruiting | Sponsor: University of Miami
New P4 trial • Back Pain • Musculoskeletal Pain • Pain
March 26, 2026
Local Methotrexate Injections for the Treatment of Nail Psoriasis
(clinicaltrials.gov)
- P4 | N=1 | Active, not recruiting | Sponsor: Weill Medical College of Cornell University | Enrolling by invitation ➔ Active, not recruiting | N=10 ➔ 1 | Trial completion date: Jan 2026 ➔ Jun 2026 | Trial primary completion date: Jan 2026 ➔ Jun 2026
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis
March 25, 2026
A triamcinolone acetonide palmitate nanoemulsion eye drop delivered by iontophoresis for the management of posterior uveitis.
(PubMed, Int J Pharm)
- "Safety evaluations confirmed its favorable biocompatibility, with no detectable ocular irritation or tissue injury. The TAP-NE system combined with iontophoretic delivery developed in this study offers a novel strategy for addressing uveitis as well as other ocular conditions associated with inflammatory processes."
Journal • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis • GFAP
March 24, 2026
Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants
(clinicaltrials.gov)
- P2 | N=3 | Terminated | Sponsor: Washington University School of Medicine | N=100 ➔ 3 | Trial completion date: Dec 2026 ➔ Mar 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Mar 2026; low recruitment
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Inflammation
March 20, 2026
Assessment of Different Treatment Modalities for the Treatment of Oral Lichen Planus.
(PubMed, J Pharm Bioallied Sci)
- "105 patients were divided into groups of 35 each to receive either triamcinolone acetonide (0.1%), tacrolimus (0.03%), or oral nanocurcumin (500 mg)...Nanocurcumin can be used for maintenance phase after initial symptomatic treatment of oral lichen planus by conventional treatment modalities. Further studies with a longer regimen period and follow-up is required."
Journal • Dermatology • Dermatopathology • Lichen Planus • Pain
March 19, 2026
Microneedling for Burn Hypertrophic Scars
(clinicaltrials.gov)
- P=N/A | N=36 | Active, not recruiting | Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Recruiting ➔ Active, not recruiting
Enrollment closed • Dermatology
March 18, 2026
Scalp Alopecia After Greater Occipital Nerve Block Administration Mimicking Alopecia Areata.
(PubMed, Am J Dermatopathol)
- "We report 3 cases of localized occipital alopecia after greater occipital nerve block injections containing triamcinolone acetonide 40 mg (1 mL)...These findings highlight an underrecognized iatrogenic cause of patchy scalp alopecia that may mimic alopecia areata. Recognition of this entity is important to avoid misdiagnosis and unnecessary treatment."
Journal • Alopecia • Immunology • Lipodystrophy
March 18, 2026
Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone Acetonide and Vancomycin as Representative Intravitreal Agents.
(PubMed, Clin Ophthalmol)
- "Fixed dosing strategies may increase peak exposure and IOP load in small eyes and shorten effective therapeutic duration in large myopic eyes. Biometry-stratified clinical studies are warranted to validate these modeling predictions and to assess their clinical relevance in intravitreal antibiotic and corticosteroid therapies."
Journal • PK/PD data
March 18, 2026
SIALENDOSCOPY VERSUS PHOTOBIOMODULATION IN PREVENTION OF RADIATION INDUCED XEROSTOMIA
(clinicaltrials.gov)
- P=N/A | N=42 | Recruiting | Sponsor: Alexandria University
New trial • Dental Disorders • Head and Neck Cancer • Oncology • Solid Tumor • Xerostomia
March 17, 2026
SIDE-RFA: Sidekick vs Conventional Cannula in Lumbar Medial Branch Radiofrequency Ablation
(clinicaltrials.gov)
- P=N/A | N=82 | Completed | Sponsor: Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
New trial • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain
March 17, 2026
Comparing Punch Excision Combined with Triamcinolone Acetonide and 5-Fluorouracil Injection and Manual Fractional Technology Combined with Triamcinolone Acetonide and 5-Fluorouracil Injection in Keloids: A Single-Blinded Randomized Clinical Trial.
(PubMed, Aesthetic Plast Surg)
- "This study demonstrated that punch excision combined with TAC&5-FU, as well as MFT combined with TAC&5-FU, was promising therapeutic options for keloids without a notable difference in effectiveness and safety."
Clinical • Journal • Fibrosis
March 17, 2026
TREAT-OT: Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease
(clinicaltrials.gov)
- P=N/A | N=15 | Completed | Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana
New trial • Ophthalmology • Thyroid Eye Disease
March 16, 2026
Exploring the Effect of Surface Hydrophilicity of Nanoparticles on Ocular Posterior Transport Pathway via Non-Invasive Topical Administration.
(PubMed, Adv Healthc Mater)
- "Herein, triamcinolone acetonide-loaded NPs with different surface hydrophilicity were prepared by mixing poly(lactide-co-glycolide) and poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) at different ratios...After dropped twice daily for 14 days, 3.5% and 16.7% PEG NPs reached comparable therapeutic effect with intravitreal injection. This study demonstrated the significance of NPs surface hydrophilicity in posterior delivery, providing theoretical basis for rational design of NPs for ocular posterior diseases therapy by topical dropping."
Journal • Age-related Macular Degeneration • Retinal Disorders
March 12, 2026
Sjögren's Syndrome and Primary Localized Cutaneous Nodular Amyloidosis: A Plasma Cell–Driven Association
(AAD 2026)
- "Case: A 27-year-old woman with seropositive rheumatoid arthritis and SS (on hydroxychloroquine 250 mg daily) presented with two pruritic nodules on the left leg progressively enlarging over three years...Treatment included topical halobetasol 0.05% for one month, five monthly intralesional triamcinolone acetonide injections (20 mg/mL), and surgical curettage, achieving complete resolution without recurrence at 8 weeks... PLCNA should be considered in SS patients with cutaneous nodules, even at young age. Early recognition, full systemic evaluation, individualized therapy, and periodic follow-up optimize outcomes and detect systemic disease. Keywords: PLCNA, Sjögren's syndrome, AL amyloidosis, dermoscopy, intralesional corticosteroids."
Amyloidosis • Dermatopathology • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Sjogren's Syndrome
March 15, 2026
Comparative Evaluation of Therapeutic Effects of Boric Acid and Triamcinolone in Nasal Polyp Culture.
(PubMed, Biol Trace Elem Res)
- No abstract available
Journal • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
February 23, 2026
Drugs for atopic dermatitis.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 13, 2026
Multiple Evanescent White Dot Syndrome After mRNA COVID-19 Vaccination.
(PubMed, Cureus)
- "Full-field electroretinography (ERG) showed reduced amplitudes of both a- and b-waves...The day after the initial visit, the BCVA in the right eye rapidly declined to 0.01 in decimal units, prompting the initiation of oral prednisolone at 30 mg/day. Eight days later, a sub-Tenon's capsule injection of triamcinolone acetonide (20 mg/0.5 ml) was administered...Oral steroid therapy was tapered, and the visual acuity (VA) improved to 1.0 in decimal units four months later. A case of MEWDS occurring after COVID-19 vaccination showed favorable recovery with oral steroid therapy and sub-Tenon's injection."
Journal • Achromatopsia • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 12, 2026
Ultrasound-guided percutaneous galvanic current compared to ultrasound-guided intralesional corticosteroids infiltration in inflammatory tunnels of hidradenitis suppurativa.
(PubMed, Actas Dermosifiliogr)
- "Ultrasound-guided percutaneous galvanic current may constitute an intralesional treatment alternative in inflammatory and draining HS tunnels, with the potential to physically eliminate the treated lesion and with an acceptable safety profile."
Journal • Dermatology • Fibrosis • Hidradenitis Suppurativa • Immunology • Pain
March 11, 2026
Knee Injections for Obese Patients With Knee Arthritis
(clinicaltrials.gov)
- P4 | N=40 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027
Trial completion date • Trial primary completion date • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology
March 11, 2026
Triamcinolone acetonide for aesthetic refinement in rhinoplasty for patients with thick skin: the FAN technique ‒ a pilot study.
(PubMed, Braz J Otorhinolaryngol)
- "TA injection via the FAN technique is a promising adjunctive treatment for optimizing postoperative outcomes in thick-skinned rhinoplasty patients. This approach effectively reduces swelling, enhances nasal contouring, and improves patient satisfaction while maintaining an acceptable safety profile. Further studies with larger sample sizes and extended follow-up are warranted to validate these findings."
Journal • Aesthetic Medicine
December 24, 2025
Triamcinolone Acetonide Does Not Accelerate Human Cartilage Degeneration: Evidence from a Click-Chemistry Assay
(AAOS 2026)
- "Even at a supra-physiologic dose, TA did not induce chondrocyte death or accelerate matrix degradation. Click-chemistry assay revealed only a modest, reversible suppression of matrix synthesis, and high-dose TA lowered catabolic gene expression in OA cartilage. Given TA's insolubility in synovial fluid and tendency to remain on the cartilage surface clinically, intra-articular injections of TA are unlikely to reach chondrotoxic concentrations in vivo."
Inflammation • Orthopedics • Osteoarthritis • ACAN • ADAMTS5 • COL2A1 • MMP13
1 to 25
Of
2198
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88